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STUDY OF CARDIOVASCULAR MANIFESTATIONS IN   
   HYPERTHYROIDISM 
 
ABSTRACT 
 
BACK GROUND AND OBJECTIVE: 
 
  Thyroid disorders are the most common among all the endocrine diseases in 
India. Hyperthyroidism (thyrotoxicosis) is widely prevalent in India in the age 
group of 16-23 years, women affected ten times more than men.Thyroid hormone 
directly affect the heart and peripheral vascular system causing increased heart rate 
and cardiac output .Atrial arrhythmias,congestive cardiac failure and rarely 
Valvular lesion occur in Thyrotoxicosis. Hyperthyroidism results in increased 
mortality due to circulatory disease and dysrhythmias. Incidence of cerebral 
embolism more common in hyperthyroidism with Atrial fibrillation occurring in 
elderly and Anticoagulation is indicated in them.Early treatment results in 
reversion to sinus rhythm in upto 2/3 of the patients.Beta-blockers reduce left 
ventricular hypertrophy andatrial and ventricular arrhythmias in patients with 
hyperthyroidism. 
 
METHODOLOGY: 
 Seventy patients full filling the study criteria were recruited in this study.  
RESULTS:  
 Study included 60 females and 10 males in the ratio of 6:1.Incidence of 
Hyperthyroidism is more common in the age group of 30-49yrs.commonest 
symptoms were Palpitation( 79% ) , Heat intolerance (69%)Fatigue(66%)tremor in 
hands(11%),weight loss(50%). Signs are Tachycardia(80% ),increased Blood 
pressure and Pulse pressure, ECG and ECHO shows Sinus tachycardia(80%), 
Atrial fibrillation( 17%) ,Chamber enlargement( 13% )(14% )  had Mitral 
regurgitation and (3% ) had Mitral valve Prolapse.Chest x ray PA view shows (20 
%) had Cardiomegaly in our study. 
INTERPRETATION  AND CONCLUSION: 
 Thyrotoxicosis was common in the Third decade of life.Females were more 
commonly affected than males. Cardiovascular symptoms were palpitations, 
dyspnea, chest pain and signs were tachycardia,widened pulse pressure  andpedal 
edema.Chest X-ray showed Cardiomegaly.ECG changes were sinus tachycardia, 
Atrial fibrillation. Echocardiogram showed chamber enlargement, Mitral 
regurgitations and Mitral valve prolapse. In our study younger patients were more 
affected with hyperthyroidism(thyrotoxicosis) with Cardiac manifestations.Patients 
were improved  wellafterearly diagnosis and treatment in our study. 
KEYWORDS:  
 Hyperthyroidism, Palpitation, Arrhythmias, congestive cardiac failure 
,valvularlesion, anticoagulation, Betablockers,. 
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INTRODUCTION: 
Thyroid means (Greek  thyreos means Shield, plus  eidos,  form) Thyroid  
disorders is the   commonest endocrinological disorder in clinical practice after 
diabetes mellitus.  Hyperthyroidism is defined in   a   state  of excessive  thyroid 
gland function. Thyrotoxicosis is defined as the state of thyroid hormone excess 
and  causes clinical Cardiac, Neurological,  Ophthalmological , Dermatological, 
Gastro- intestinal , Endocrinological  symptoms and signs. Hyperthyroidism 
caused by Grave’s disease, Multi nodular goiter and  Toxic adenomas constitute 
about majority of the cases of thyrotoxicosis. Grave’s disease accounts for about 
60-80% cases of thyrotoxicosis
1
.  
Thyroid hormone exerts wide spectrum   Physiological, Bio chemical 
effects on   Multi organ system functions. The clinical presentation depends on 
the   disease of duration, severity, age   to   the   hormone levels in   blood 
1 
. 
Hyperthyroidism causes a wide range of clinical manifestations signs and 
symptoms. They include general features like hyperactivity, heat intolerance, 
easy fatigability, weight loss and neurological, cardiac, dermatological, 
ophthalmological, gastrointestinal and  endocrinological manifestations.   
Heart is mainly affect as T3, T4 has major effects on the Cardiovascular 
function and hemodynamics produce after significant derangement in function. 
Hyperthyroidism
 
which is associated
 
with tachycardia, increased LV workload, 
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SVT like AF. The common presentation of hyperthyroidism include 
tachycardia, wide pulse pressure, atrial fibrillation, brisk pulses, loud first heart 
sound and a hyper dynamic cardia apex
4 ,5
. 
 In hyperthyroidism patients Cardiac involvement is of great prognostic 
importance and causes significant morbidity and mortality. All the more 
affected patients are potentially reversible also with early diagnosis and 
appropriate treatment. Secondary complications like cerebral stroke can be 
associated arise from atrial fibrillation
58
. Cardiac problems resolves rapidly, 
when hyperthyroidism is treated with anti thyroid drugs and   thyroid hormone 
return to normal level. Early and prompt diagnosis of cardiac symptoms and 
signs and early appropriate treatment prevents most of the complications of 
hyperthyroidism. In addition to that most of the cardiac features are the 
presenting symptoms and signs of hyperthyroidism and thyrotoxicosis. Early   
diagnosis   of   the cardiac   features   is also not a difficult issue. Good clinical 
examination, an Electrocardiogram and an Echocardiogram are the essential 
requirements for early diagnostic modality for cardiac abnormalities. 
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Knowledge of cardiac manifestations of hyperthyroidism is difficult for 
early diagnosis of hyperthyroidism as well as the early prompt recognition of its   
clinical complications. An individual susceptibility to excess thyroid hormone is 
an important factor determining the clinical manifestations, there may be most 
of genetic and regional variations can occur.  
Hence a study of local population is needed. The present study was 
undertaken because of study of   the cardiac manifestations   like symptoms and 
signs of hyperthyroidism and their correlation with thyroid hormone levels and   
with the outcome of treatment and follow up period for six months. 
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OBJECTIVES 
 
AIMS OF THE STUDY: 
1. To assess the biochemical, clinical, cardiac profile of cases with 
hyperthyroidism                                             
2. To correlate the thyroid hormones levels with severity of clinical 
symptoms and correlations. 
3. To compare the clinical outcomes after treatment and follow up period 
after   six   months   of treatment. 
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REVIEW OF LITERATURE: 
Robert J. Graves (1796-1853) described about “four cases of   severe 
palpitation in females with thyrotoxicosis”. 
 
 C. von Basedow , described in 1840 three cases with goiter, exophthalmos and   
palpitation in the European continent and also noted the cardiac aspects of 
hyperthyroidism 
 
Barbisan J.N et al have found high prevalence of acute atrial fibrillation in 
patients with hyperthyroidism   and described that T3, T 4, TSH estimation is   
mandatory
74
. 
 
 In Hyperthyroidism patients have Atrial fibrillation   incidence   about  9-
22%
34
.  In general population prevalence of  0.4 - 4%. 
 
In Hyperthyroidism most responsive and   most sensitive   organ is heart   and 
thyroid hormone exerts effects on cardiovascular system by various 
Physiological and Biochemical and Nuclear Receptor actions.  
 
In hyperthyroidism  , Cardiovascular  manifestations  which  include 
palpitations,   angina,  fatigue,  systolic  hypertension  and congestive cardiac 
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failure .For that  40% of patients   have sinus tachycardia   and  15% of patients 
have  atrial fibrillation
34
. 
 
In Hyperthyroidism   Other clinical manifestations include a Pulse:  High 
sleeping pulse rate, high volume collapsing pulse water hammer in nature due to 
wide pulse pressure, Carotid dance and Suprasternal pulsations,  Apex:  hyper 
dynamic  normal in position, First and pulmonary second heart sound and Third 
sound due to tachycardia.  
The recurrence of MVP/MR is increased when associated with 
hyperthyroidism
47
. Systolic murmur  at the Apex due to increased blood flow.  
  
Means-Lerman scratch- To and Fro scratchy sound is heard in the Pulmonary 
area in Mid systole due to   Rubbing of pleura and pericardium as a result of 
Hyperkinetic circulatory state in Hyperthyroidism
34
.  
 
Hyperthyroidism present as Palpitation with sweating, Angina pectoris and 
Dyspnea with congestive cardiac failure indicating that changes in 
cardiovascular system hemodynamics
32,33
. 
Cardio vascular system may be the primary indication of thyroid dysfunction   
in all   symptomatic   patients with cardiovascular disease. 
 
  
7 
 
Thyrotoxicosis is most commonly produces high cardiovascular disability and 
mortality. Primarily due toPalpitations,Atrial fibrillation, Diastolic dysfunctions, 
Congestive cardiac failure, thromboembolism and Stroke
58
.  Clinically patients 
with palpitations, dyspnea on exertion, exercise intolerance and other 
cardiovascular manifestation. Sinus tachycardia is the most common initial 
cardiovascular signs; one should suspect possibility of Thyrotoxicosis. 
 
Arrhythmia   associated with   hyperthyroidism and   thyrotoxicosis   includes 
atrial fibrillation and atrial premature contractions. Very rarely presented with 
ventricular tachycardia and ventricular  fibrillation.  
All cases with AF is the indication of evaluation of Hyperthyroidism and 
Thyrotoxicosis Zargar A.H. et al in their study “Clinical and endocrine aspects 
of thyrotoxicosis and its cardiovascular complications in 203 subjects found                            
sinus tachycardia in 63.5% of patients. The other cardiac manifestations were 
atrial fibrillation (8.9%). Cardiomegaly (9.8%), Cardiac failure (7.4%) and left 
ventricular hypertrophy (5.4%). Various types of heart block were observed in 
2.5% of patients.11% of patients had tachycardia as the most common cardiac 
manifestation
75
. 
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Anatomy of Thyroid gland: 
Figure1:  
‘Thyroid  Gland (Glandula Thyreiodea)  is  a highly vascular organ and   situated  at  
Front   and   sides of the neck. It consists of right and left lobes connected across the 
Midline   by a narrow   portion called   isthmus. Its weight is usually about 30 grams. It is   
slightly  heavier in the female and increased in size  during menstruation and Pregnancy. 
 
 Development of thyroid gland: 
 
The thyroid gland is developed from a median   diverticulum ,  which  appears on  the 
 
 4th Week   on the   summit  of the  tuberculum  impar,  but later is found in the furrow  
 
Immediately behind   the  tuberculum. It grows downward and backward as  a tubular  
 
duct, then bifurcates and subsequently subdivides into a series of cellular cords, from  
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which the isthmus and lateral lobes of the thyroid gland are developed.  The ultimo- 
 
branchial   bodies from the 5th  pharyngeal pouches are enveloped by the lateral lobes  
 
 of the thyroid gland, they undergo atrophy and do not form true thyroid tissue.  The  
 
connection   of the diverticulum with the pharynx is termed the  thyroglossal duct;  its  
 
continuity is  subsequently interrupted and it undergoes degeneration,  it’s upper end   
 
being   represented by the  foramen cecum of the tongue and  its lower by the  Pyrimidal  
 
lobe of thyroid gland. 
 
Physiological functions of thyroid: 
The thyroid gland is the most important Endocrine organ produces two vital 
hormones namely   T3/T4 which is important for all cell metabolism in the 
body, cell growth and differentiations during intrauterine life and development.  
Thyroid hormones acting through nuclear receptors, these thyroid   hormones   
in addition   help   to maintains   thermo genic and metabolic homeostasis in all  
human beings. Disorders of thyroid gland can   be primarily   divided into 
Disorder of excessive   thyroid gland function (Hyperthyroidism), Excessive 
productions of thyroid hormones (Thyrotoxicosis) and low productions of   
thyroid hormones (Hypothyroidism). Hyperthyroidism denotes excessive 
thyroid function. Hyperthyroidism most commonly   caused by   Grave’s 
disease, MNG and Thyroid adenomas   associated with   thyrotoxicosis. Grave’s 
disease constitute about   60-80% of thyrotoxicosis.
1 
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Molecular Background: 
The thyroid gland produces a proactive molecule namely T4 which is 
converted to T3 by iodination. The T3 exerts action by binding to nucleic acid 
receptor and producing physiological response. 
Thyroid Hormone Related Receptors action: 
These receptor belonging to nuclear receptor super family (analogues to 
Vitamin D3receptor and Retinoic acid receptor).this receptor encoded by TR 
alpha(alpha 1&2) and TR beta genes. The ligand binds to the non –histone 
protein portion of the DNA mostly in the carboxy terminal to bring about 
increase in mRNA, r RNA productions and related effects. The T3 receptor 
binds as homo or heterodimers on nucleic acid. The ligand binding domain 
confers specificity for T3 and mutation in these can lead to hormone resistance. 
Heptad motifs important for dimeric interaction. The TR alpha is clinically 
more significant than TR beta, it’s mostly expressed on gastro-intestinal system, 
reproductive system, cardiovascular system, brain, brainstem, cerebellam, 
corpus striatam and hypothalamus
13,14
.    
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Types of Thyroid Hormone Receptors: 
T3 receptors   are alpha1, alpha2, beta1 and beta2. The Brain contains
 
mostly T3 
receptor alpha, and the liver contains   T3 receptor beta; cardiac muscle
 
contains 
both alpha and beta receptors
16          
Effects of Thyroid Hormone on the Cardiovascular System: 
Increased action of T3,T4 to  certain molecular
 
pathways in the Cardio vascular 
system produces marked cardiovascular
 
derangements. Hyperthyroidism
 
causes a 
hyper dynamic cardiovascular state (i.e) increased cardiac output
 
 and reduce SVR  
causes
 
 increased, rapid heart rate and augmented LV systolic
 
and diastolic function, 
and increased incidence  of SVT  like  atrial fibrillation. Cardiovascular
 
system 
responds to circulating
 
T3, T4 levels causes permanent changes. Subclinical 
hyperthyroidism
 
also causes sinus tachycardia, AF,
 
augmented LV mass, diastolic 
dysfunction,
 
exercise intolerance, and increased risk of cardiovascular mortality. 
Because all of these cardiovascular changes are reversed by appropriate early 
treatment is indicated to reduce  cardiovascular mortality and morbidity
 3             
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Figure:2
 
 In human at rest increased   cardiac output   due to this Pathophysiological 
mechanism of Thyroid hormones.  (Dotted line represents inhibitory action).  
 
SVR- Systemic vascular resistance 
 RAAS- renin-angiotensin-aldosterone system   
DAP- Diastolic arterial pressure  
SAP- Systolic arterial pressure      
  AP- arterial pressure 
LVEDV-  LV end-diastolic volume.  
LVESV-  LV end-systolic volume. 
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Cellular Effects of Thyroid Hormone on the Cardiovascular 
System: 
 Molecular and cellular mechanism of T3, T4 to the cardiovascular system is 
described. Figure1 described about T3,T4 may produce genomic
 
, non- genomic 
effects on cardiac myocytes
17
.  
The genomic action of T3,T4  is initiated  by the transcriptional activation
 
or 
repression of specific target genes which  encode  structural
 
and functional proteins
17
. 
This process begins
 
with the entry of triiodothyronine (T3) into the cardiomyocyte. To 
date, there is no clear evidence of a biologically relevant
 
conversion of thyroxine (T4) 
to T3 in cardiomyocytes
18. 
In the cardiomyocyte, T3 enters the nucleus
 
and interacts 
with specific transcriptional activators (NR alpha1) or repressors (NR alpha2). T3
 
receptor in combination with cofactors,  
 
forms  the thyroid hormone-receptor complex 
to bind (NR alpha-1) or release (NR alpha-2) and  specific sequences
 
of DNA 
(thyroid-responsive elements)  acting
 
as cis or trans regulators modify the rate of 
transcription
 
of specific target genes
19
 . 
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Figure 3.Genomic action of  T3  on  cardiomyocytes. 
 
 (NR- Nuclear receptor;    TRE- Thyroid hormone responsive element.) 
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 The other proteins are modulated at transcriptional
 
levels like myosin
 
heavy chains (MHC) and the sarcoplasmic
 
reticulum protein called Calcium 
dependent Adenosine tri phosphatase   and it’s inhibitory cofactor named 
Phospholamban
17,20
.  T3, T4 up regulates  the
 
alpha isoform of the MHC in 
cardiomyocytes  and  down regulates the beta isoform
21,22
. In humans,  excess of 
beta isoform
 
of MHC produces Cardio vascular effects by endothelium 
dependent
 
and nondependent mechanisms
31
 . 
Physiological Effects of Thyroid Hormone on   Cardiovascular 
System: 
Thyroid hormone and heart rate : 
Thyroid hormone causes increased heart rate,
 
resting sinus tachycardia is  
commonly seen Cardiovascular system
 
sign of human hyperthyroidism and 
thyrotoxicosis 
32
. The increase in heart rate
 
does not constant during First twenty 
four hours. Circadian rhythm variability  
 
is well maintained than normal cases
 33 
.Increased occurrence of AF has observed   in cases with hyperthyroidism
 34
. 
The increase in cardiac contraction, output and rate in hyperthyroidism
  
 cases   
is   may be due to imbalanced sympathetic-parasympathetic activity
 
due to an 
absolute sympathetic excessive drive
35
.  Correlation between T3,T4 value
 
and 
nocturnal  sleeping  heart rate in hyperthyroidism, thyrotoxicosis  cases  
indicates  that T3,T4 may  be  affect  SA node firing 
33,36,37
. 
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Thyroid hormones effects on afterload of heart: 
Ventricular afterload is reduced in hyperthyroidism patients. Thyroid
 
hormone directly   increase arterial smooth muscle relaxation causes to  
reduction  in systemic vascular
 
resistance will occur.  
Hyperthyroidism: 
Hyperthyroidism caused by Grave’s disease, MNG and Toxic adenomas 
account for most of the cases of thyrotoxicosis.  
Grave’s Disease (GD): 
Grave’s disease accounts for 60-80% of thyrotoxicosis1. Grave’s disease 
occurs in 2% of women   population, but is 1/10 as frequent in men. It 
commonly occurs in the age group 20-50 years of aged populations
52
. 
The pathogenesis of grave’s disease involves a combination of   
autoimmune and genetic causes. Comparatively   smoking   contributes   small   
risk   causes of GD and higher complication of   ophthalmological   problems  
may occur. There is a four-fold increase in incidence of grave’s disease in post- 
partum state. Hyperthyroidism, thyrotoxicosis of GD is due to thyroid 
stimulating immunoglobulins.  TPO (Thyroid peroxidase antibodies) may occur 
in 60-80% of cases. TPO most commonly associated with autoimmune disorder 
Hashimoto’s thyroiditis than GD. 
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 Multi nodular goiter (MNG): 
Multi nodular goiter occurs (MNG) in up to 10% of adults. Multi nodular 
goiter is affected more in   women, men’s are   less affected. 
Pathogenesis involves a combination of environmental, autoimmune and 
genetic factors. Most nodules with in a Multi nodular goiter are polyclonal in 
origin, features suggesting a of hyperplastic response to locally produced 
cytokines and   growth factors.  
Toxic Adenoma: 
An independently working   single   thyroid nodule described as   ‘ Toxic 
adenoma”. Most patients with toxic adenoma have acquired somatic, activating 
mutations in TSH-R. Thyrotoxicosis is usually mildly occur.  
Clinical manifestations of hyperthyroidism: 
The clinical presentation depends on the disease duration, severity, age 
and patients body reactivity   to increase T3/T4 levels.  
Table 1 shows :  Common symptoms of hyperthyroidism: 
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Hyper activity,  
Heat intolerance 
Palpitations 
Fatigue and weakness 
Weight loss 
Increased appetite 
Polyuria 
Oligomenorrhoea,  
Goiter 
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Table  2 shows: Neurological manifestations of hyperthyroidism: 
 
 
Tremor 
Hyperreflexia 
Muscle wasting, proximal myopathy 
Periodic paralysis 
 
 GD  that causes grave’s ophthalmopathy. Ophthalmopathy occurs in 
75% of cases of grave’s disease within one year. The features includes lid 
retraction, periorbital edema, proptosis, chemosis, extra ocular muscle 
involvement, corneal involvement, optic nerve compression and visual loss. 
Thyroid Skin lesion  contribute   in 6% of cases with GD and occurs with 
moderate to severe ophthalmopathy. It occurs commonly in anterolateral region  
of leg,  so called Pretibial myxedema”. Non-pitting  type of edema. 
Thyroid acropachy occur in less than one% of cases of grave’s disease 
described as clubbing seen in fingers and toes and is strongly associated with 
dermatopathy. In patients with hyperthyroidism, skin is usually warm and moist. 
Palmar erythema, Pruritus, Plummer nail and onycholysis of nails   may occur. 
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Gynaecomastia is rarely noted in men.  Hypocalcaemia Osteopenia and 
fractures of long bones   may be occur but rare. 
Cardiac Symptoms: 
Most of the patients have palpitations, have a rapid heart rate   and the 
sensation of forceful cardiac contraction 
42, ,43
.  Rarely atrial rhythm disturbances 
may produce a sensation of   an irregular heart rate or an   increase   heart rate or 
both events can occur. The sensation of exercising while at rest   indicates   the 
continuous   high cardiac output state. Other common cardiac manifestations in 
hyperthyroidism and thyrotoxicosis are exercise intolerance and breathlessness 
on exertion. 
In older patients   mostly with initial features may be presented to tachycardia, 
probably due to paucity of adrenergic activity. With the onset of atrial 
fibrillation and extent of cardio vascular features may be exaggerated, 
proceeding to cardiac failure and edema.  
Thyrotoxicosis   cases may have chest discomfort   similar to angina, 
probably caused by relative myocardial ischemia due to mismatch between 
increased oxygen demand and cardiac oxygen   supply, coronary vasospasm
44
. 
The chest discomfort symptoms commonly disappear with treatment. In older  
patient with, hyperthyroidism may mask the effect coronary artery heart 
disease. 
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Cardiac Signs: 
Tachycardia is the commonest cardiac sign in hyperthyroidism.  The 
mean blood pressure is may be normal. In older patients may have an increase  
Systolic blood pressure due to elastic components of arteries and a resulted 
elevated mean arterial pressure. 
The carotid and peripheral arterial pulsations are may be hyper dynamics 
and brisk.  There is a hyper dynamic precordial region with loud First heart 
sound, loud P2 and rarely Third heart sound and ejection click. Mid systolic 
murmur along the left sternal border usually heard due to increased flow. It is 
probably due to the rubbing together of normal pericardial and pleural surfaces 
by the hyper dynamic and circulatory heart. Auscultation over   pulmonary areas 
shows pulmonary flow murmurs. Systolic murmurs of mitral and tricuspid 
regurgitation, secondary to papillary muscle dysfunction may occur. Patients 
with Grave’s disease may have a higher incidence of mitral regurgitations and 
mitral valve prolapse as diagnosed by echocardiography
47
. This effects probably   
may be due to hemodynamic effects of hyperthyroidism rather than genetic 
factors. 
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Atrial Fibrillation: 
 In hyperthyroidism, thyrotoxicosis commonest ECG finding is Atrial 
fibrillation. This supra ventricular arrhythmia may occur of   two–twenty 
percent hyperthyroidism
 
cases. In hyperthyroidism constitute about   five–
fifteen percent 
 
 newly identified cases of Atrial fibrillation.  In
 
Atrial flutter and 
other forms supraventricular tachyarrhythmias are very rare in hyperthyroidism 
and thyrotoxicosis.  Occurrence of Ventricular fibrillation and ventricular 
premature contractions are also very   rare in thyrotoxicosis.
40 
Electrocardiogram   changes in Hyperthyroidism: 
 In hyperthyroidism cases electrocardiogram shows sinus tachycardia in 
most of the cases. Atrial fibrillation is noted in 12-18% of cases. Atrial 
fibrillation is seen more common in   younger and elderly age patients. Sinus 
tachycardia is more in young individuals whereas atrial fibrillation is seen 
commonly in young and elderly. The electrocardiogram often shows widespread 
nonspecific ST-segment elevation and upward coving with terminal T wave 
inversion in about one third of cases. Intra atrial conduction abnormality may 
occur and prolongation PR interval occurs in 8-12% cases. Other rare findings 
may include shortening of QT interval, right bundle branch block, First, second 
or third degree heart block and paroxysmal supraventricular tachycardia 
40, 41 , 61
. 
Chest X-ray in hyperthyroidism: 
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In patients with hyperthyroidism without cardiac disease X ray chest PA 
view is usually normal. In patients with cardiac manifestations may have   
Cardiomegaly. Prominent   Pulmonary artery, aorta and left ventricle may be 
seen
76
. 
Echocardiographic abnormalities in hyperthyroidism: 
Left ventricular contractility   enhanced in patients with   hyperthyroidism 
and   thyrotoxicosis   as compared with age related normal subjects. The
 
augmented Cardiac output may be   due to raised heart
 
rate and stroke volume. 
As a result of   Left ventricular ejection fraction, systolic function, increased in  
hyperthyroidism patients
62
. Cases of   hyperthyroidism and thyrotoxicosis 
shows   elevated LV systolic and diastolic contractile function. In 
hyperthyroidism cases Echocardiographic findings include cardiomegaly, 
diastolic dysfunction left ventricular hypertrophy, dilated cardiomyopathy, 
mitral regurgitation and mitral valve prolapse. Rarely systolic dysfunction is 
noted
64
. 
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Management of Hyperthyroidism: 
The hyperthyroidism, thyrotoxicosis is managed by anti- thyroid drugs or with 
radio iodine treatment (
131
I) or by subtotal thyroidectomy. Anti- thyroid drugs 
are the predominant therapy in main modality of   treatment   is   radio- active 
iodine is the first line treatment in South America. The   differences   reflecting   
the fact that no single approach is adequate and patients may require multiple 
level approach treatments to control hyperthyroidism and thyrotoxicosis. 
Drugs usage to control hyperthyroidism: 
Common drugs are Thionamides like Propylthiouracil, Carbimazole & 
Methimazole. All these drugs inhibit the function of thyro peroxidase enzyme, 
mechanism of action   reducing oxidation & formation of iodide.  
Propylthiouracil  inhibits  deiodination of Thyroxine  to  Triiodothyronine. 
The initial dose of carbimazole or methimazole is 10-20 mg every 8-12 
hourly. Propylthiouracil is given at a dose of 100-200mg every 6-8 hourly. 
Lower doses of drugs suffice in areas of low iodine intake.  
TFT, symptoms, signs are reexamined   after 2-3 weeks to initiating 
treatment and drugs doses may be reduced   according to the unbound 
Thyroxine (T4) levels. The usual maintenance doses of anti -thyroid drugs are 
2.5 –10.0mg of carbimazole, methimazole and 50-100mg of propylthiouracil. 
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Maximum treatment control   may be attained by two years. Patients with severe 
hyperthyroidism and large goiters are likely to relapse when treatment stops 
suddenly. Propranolol may be helpful in controlling sympathetic signs, 
importantly   before   anti thyroid medications   to control symptoms and signs.  
Radio iodine : 
Radio iodine can be used for initial treatment or for relapses after anti 
thyroid drug treatment. There is a small risk of   thyrotoxicosis crisis, can be 
prevented with prior treatment with anti -thyroid drugs. Antecedent treatment 
with anti -thyroid drugs should be considered for young and elderly patients and 
those with cardiac manifestations, to deplete thyroid hormone stores. Anti -
thyroid drugs should be stopped minimum Three days prior to ensure optimum 
iodine uptake.
131
I dosage ranges between185MBq and 
555MBq.Hyperthyroidism can persist for 2-4 months post radio iodine therapy, 
for which beta blocker and anti- thyroid drugs like  carbimazole or  
methimazole  may be required. Persistent hyperthyroidism and thyrotoxicosis 
may be managed   by 2
nd
 cycle   of radio iodine therapy after six months may be   
useful
56
. 
Subtotal thyroidectomy: is an alternate   option for patients who 
relapse after anti -thyroid drugs. Some experts recommend surgery in the young 
particularly if the goiter is large and presence of pressure symptoms, 
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management of hyperthyroidism and supplementation of KI is required prior to 
surgery to reduce the vascularity and to avoid life threatening events like   
thyrotoxicosis crisis. 
Ophthalmopathy usually requires no active treatment if it is mild. 
However, in severe cases may requires   Inj. methyl prednisolone pulse or high 
dose oral glucocorticoids needed. Orbital decompression may be the treatment 
of choice in severe cases. Thyroid dermopathy may be managed with topical 
steroids therapy. Octreotide   (somatostatin   analogue) may be beneficial to the 
patients with opthalmopathy. 
Management of toxic Multi nodular goiter is challenging one. Anti -
thyroid drugs and beta-blockers normalize   thyroid gland function. However 
they stimulate growth of goiter. Radio iodine is an option especially in the 
elderly usually more than 40 years of age. Surgery however is the definitive 
treatment for goiter as well as thyrotoxicosis. Radio iodine is the preferred 
treatment for toxic adenoma patients. Finally   enucleation   of adenoma or  
thyroid lobectomy indicated in  refractory to medical management cases. 
 
 
 
  
27 
 
Management of  thyrotoxic  heart disease: 
Heart rate reduction in patients of hyperthyroidism with or without 
cardiac disease is best controlled with beta-blockers. The goals of therapy are to 
slow down the heart rate, decrease symptoms and signs of cardiac 
decompensation and maintain blood pressure. Propanolol used cautiously in 
patients with cardiac decompensation state. They can be used synergistically 
with cardiac glycosides like tab. digoxin 0.25mg to reduce heart rate and is of 
benefit if cardiac failure is  due to tachycardia
66
.Iodine acts quicker than anti-
thyroid drugs and hence may be used for rapid amelioration od hyperthyroidism  
state in patients with thyrotoxicosis cardiac disease
67   
Patients with cardiac 
failure require digoxin and diuretics. When the situation   beta-blockers are 
contraindicated, calcium channel blockers may be indicated   for heart rate 
control. In hyperthyroidism cases   have AF requirement of  anticoagulant drugs 
may not be useful.  
Hyperthyroid heart disease and response to treatment: 
Treatment of hyperthyroidism control cardiac symptoms and signs in 
most of the cases. In hyperthyroidism   aim of treatment is   reversal of 
 
 atrial 
fibrillation to NSR.  With earlier appropriate   treatment, thyrotoxicosis 
cardiomyopathy is totally reversible
72
.finally with effective and intensive   line 
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of treatment, cardiac symptoms, signs and functions revert to normal sinus 
rhythm in most of the cases.  
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MATERIALS AND METHODS: 
Study population and design: 
This is a descriptive, clinical   and   prospective study   comprising   of   
seventy   cases  of  hyperthyroidism, thyrotoxicosis  Patients  attending  medical 
OPD or admitted in medicine wards, Department of  Internal Medicine,  
Thanjavur  Medical College and Hospital . During the period from October 
2011- November 2012.Informed consent obtained from all patients. 
 Inclusion Criteria: 
 Patients of newly diagnosed and untreated hyperthyroidism, 
thyrotoxicosis  attending medical OPD or admitted in medicine wards, 
Department of  Internal Medicine , Thanjavur Medical College and Hospital, 
Thanjavur. Hyperthyroidism was defined as 
 Serum T3 level  >   200 ng/dL 
 Serum T4 level >   12 mcg/dL 
 Serum TSH level <  0.3mU/mL 
 (Measured by radio immuno assay method) 
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Exclusion Criteria: 
Patients already diagnosed cases of Hyperthyroidism on regular 
treatment. Unwilling   for   informed consent   and   patients   who were   
participate   in   this     descriptive and prospective study    and   follow up after 
six months period of treatment.  
Method: 
Patients attending medical OPD or admitted in medicine wards with 
clinical   features   of   hyperthyroidism   symptoms and signs are examined 
clinically and diagnosed by the following biochemical methods and Imaging 
investigations. 
Complete blood picture/Peripheral smear study. 
Urine routine 
RBS 
RFT 
Sr. Electrolytes 
TFT   
LFT 
Lipid profile analysis 
Sr. Calcium 
Sr. Phosphorus 
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X-ray chest PA view 
 ECG  
Echocardiogram 
FNAC Thyroid gland 
USG   Neck 
The patients were regularly followed up after 6 months of   initial 
evaluation   and   patients   were   re-evaluated with clinical examination, 
thyroid function test, Chest X-ray, ECG and Echocardiogram. 
To appreciate   and elicit the association and comparison between   different   
parameters Pearson’s   Chi-Square” test formula was used .For all statistical 
purposes a two tailed probability of P value <0.05 was considered to be 
significant.  
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OBSERVATIONS AND RESULTS: 
 
Demographic Profile: 
 
Age of Presentation: 
The mean age of presentation was 42.08 years. The youngest patient was 
18 years and the eldest was 72years. 63% of patients were between 
30and49years of age. 25% of patients were above 50 years of age. Whereas 
12% of patients less than 30 year  of age.  
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Figure4: Age distribution of 70 cases of hyperthyroidism. 
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Table3 shows :  Age distribution and etiology of hyperthyroidism: 
Age group 
(years) 
Grave’s 
(n=42) 
MNG 
(n=25) 
Solitary 
nodule 
(n=03) 
>70 years 1 2 0 
60-69years 3 3 0 
50-59years 6 3 0 
40-49years 14 6 0 
30-39years 12 10 2 
20-29years 4 1 1 
<20years 2 0 0 
 
All patients less than 40 years had Grave’s disease. All patients with age 
more than 70 years had Grave’s and  multi nodular goiter .60%  cases of  
Grave’s disease and 36%  cases of  MNG in the age group between 30 and 49 
years. All patients with solitary nodule were between 20 and 39 years of age. 
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Sex Distribution: 
Of the Seventy cases, 85.71% (60/70) were females and 14.29% (10/70) 
were males. The male: female ratio was 1:6. 
14.29%
85.71%
Female Male
 
Figure 5: Sex distribution of 70 cases of hyperthyroidism. 
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Table  4 shows:  Sex distribution and etiology of hyperthyroidism: 
Etiology Female Male 
Grave’s  38 4 
MNG 20 5 
Solitary nodule 2 1 
 
90.47 % of cases of Grave’s disease and 80% of patients of Multi nodular 
Goiter patients were females. 
Duration of Symptoms: 
Table 5 shows: Duration of symptoms: 
Duration No of 
Patients 
Percentage 
<1 year 46 66% 
1-2 years 12 17% 
> 2 years 12 17% 
 
Majority of the patients were   had   clinical   symptoms and signs of less 
than one year duration of the illness. 
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Non-cardiac symptoms: 
 Heat intolerance and Fatigue were the commonest presenting symptoms 
of the patients.  Patients   have   less   symptoms   of   tremors only 11% of our 
study. 
 
Table 6 shows: Non cardiac symptoms in hyperthyroidism: 
Symptom No of Patients Percentage 
Heat intolerance 48 69% 
Fatigue 46 66% 
Weight loss 35 50% 
Increased appetite 20 29% 
Diarrhea 12 17% 
Oligomenorrhea 10 14% 
Tremor 8 11% 
Cardiac Symptoms: 
 The commonest cardiac symptom was Palpitations, being present in 55 
cases.79% of patients had cardiac symptoms at the time of admission. All 
patients with edema of ten cases, 14% of patients   associated with   palpitations. 
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Table 7 shows: Cardiac Symptoms in hyperthyroidism 
 
Cardiac symptoms 
 
No of Patients 
 
Percentage 
 
Palpitations 
 
55 
 
79% 
 
Edema 
 
10 
 
14% 
 
No cardiac symptoms 
 
14 
 
20% 
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Physical Signs shows: 
 
Tachycardia was present in 80% cases (56/70). The mean heart rate was 
105.86. Twelve patients (17%) had atrial fibrillation. Out of these 12 cases, 
Eleven patients had controlled ventricular rate. Thirty four patients   (48%) had 
hypertension. 42%patients had systolic hypertension were less than 60 years 
old. The mean pulse pressure was 58mmof hg.  Wide pulse pressure   of more 
than 60 mmHg was present in 36 %cases (25/70) cases. 
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Figure 6: Heart rate and Blood pressure in hyperthyroidism.  
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Cardiovascular Signs shows: 
 In this   study   54/70 of patients   had   cardiac signs (77.14%). Loud 
first heart sound (S1) was the commonest cardiac sign observed. 14.2% of   
patients   had   cardiac failure. 
 
 Table 8 shows:   Cardiac signs in hyperthyroidism: 
 
Sign No of Patients Percentage 
Loud S1 20 29% 
Ejection systolic murmur 
(pulmonary area) 
12 17% 
Cardiac Failure 10 14.2% 
Pansytolic murmur (mitral) 8 11% 
Early diastolic murmur 
(aortic area) 
4 6% 
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Neurological   signs   shows: 
 
Neurological signs were observed in 51% cases (36/70). Tremor was the 
commonest neurological sign followed by hyperreflexia. One Patient had 
proximal myopathy and   periodic paralysis. 
 
Table 9 shows: Neurological Signs in hyperthyroidism: 
Neurological 
abnormality 
No of Patients Percentage 
Tremor 36 51% 
Hyperreflexia 16 23% 
Proximal myopathy 1 1.42% 
Periodic paralysis 1 1.42% 
 
 50%   of   the   patients   had   thyroid  ophthalmopathy  (32/70).  Eight 
patients (16%) had   dermatopathy. 
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Biochemical Profile shows: 
 
The mean T3 shows 402.46 nanogram /deciliter  (normal range  60-200  
nanogram /dl), T4 shows 23 microgram/dl (normal  range 4.5-12.0 
microgram/dl) and TSH shows 0.036mU/ml (normal range 0.3-5.03mU/ml). 
Sixteen   patients   had (22%) elevated transaminases and Ten patients had 
dyslipidemia (14%). 
Table 10 shows: T3 levels in hyperthyroidism: 
T3 level (ng/dl) No of patients Percentage 
< 200 2 3% 
200-399 40 57% 
400-599 20 29% 
600-799 7 10% 
>800 1 1% 
 
57% of patient had T3 levels between 200 and 399 ng/dl. 
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Table 11 shows.T4 levels in hyperthyroidism: 
 
T4 level (mcg/dl) No of patients Percentage 
12-17 30 43% 
18-23 30 43% 
24-30 10 14% 
 
 
Table 12 shows. TSH levels in hyperthyroidism: 
 
 
TSH level (mU/ml) 
 
No of patients 
 
Percentage 
<0.009 25 36% 
0.01-0.009 35 50% 
>0.1 10 14% 
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Etiological Profile shows: 
 
Grave’s disease accounted for 60% cases (42/70),   Multi nodular goiter-
36% cases (25/70).  Three cases of solitary nodule were observed 4% in this 
study. 
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Figure 7: Etiological profile of hyperthyroidism. 
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Electrocardiogram (ECG) shows: 
ECG abnormal findings were   observed   in 80% cases (56/70). The   
commonest findings observed in ECG was Sinus tachycardia 56 cases (80%). 
Twelve of patients   had   Atrial fibrillation   was observed in 17% cases. 
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Figure 8: Heart rate. 
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Table  13 shows: ECG abnormalities in hyperthyroidism shows: 
 
ECG abnormality No of Patients Percentage 
Sinus tachycardia 56 80% 
Atrial fibrillation 12 17% 
Left ventricular hypertrophy 9 13% 
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Figure 9: Atrial fibrillation in hyperthyroidism. 
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Chest X-ray:  
Chest X-ray was normal in 56 patients. Fourteen patients (20%) had 
cardiomegaly and four patients   had   pulmonary hypertension. 
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Figure 10: Chest X-ray abnormalities in hyperthyroidism. 
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Echocardiography: 
Echocardiographic abnormalities were noted in 56% cases (39/70). 29% 
(20/70) of patients had Diastolic dysfunction was the commonest 
echocardiographic finding observed.  Ten patients   had   Mitral regurgitation 
(14%). Nine patients had Left ventricular hypertrophy (13%). Four patients had 
Pulmonary hypertension (6%). Three patients had Aortic and Tricuspid 
regurgitations (4%). Two patients had Mitral valve prolapse (3%).  
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Table 14 shows. Echocardiographic abnormalities   in  
hyperthyroidism : 
 
Abnormality 
 
No of Patients 
 
Percentage 
 
Diastolic dysfunction 
 
20 
 
29% 
 
Mitral regurgitation 
 
10 
 
14% 
 
Left ventricular 
hypertrophy 
 
9 
 
13% 
 
Pulmonary hypertension 
 
4 
 
6% 
 
Aortic regurgitation 
 
3 
 
4% 
 
Tricuspid regurgitation 
 
3 
 
4% 
 
Mitral valve prolapse 
 
 
2 
 
3% 
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The mean ejection fraction was 63.26 %. Out of the 20 patients with 
diastolic dysfunction, 29% (20/70) were above   40 years of age. 38.4 % patients 
(20/70) with diastolic dysfunction had associated hypertension. However none 
of the patients less than 40 years with diastolic dysfunction (6/13) had 
hypertension. Left atrial enlargement was seen in 33.33% (4/12) of cases with 
atrial fibrillation.  Patients with left atrial enlargement were observed more than 
50 years of age. ECG and ECHO showed left ventricular hypertrophy in 
observed for Nine   cases. 
Fine Needle Aspiration Cytology shows; 
FNAC was done in seventy cases.  
Table   15 shows: FNAC    findings   shows: 
FNAC finding No of Patients Percentage 
 
Lymphocytic 
infiltrates 
 
31 
 
44.2% 
 
Colloid nodule 
 
29 
 
41.4% 
 
Follicular cells 
 
4 
 
6% 
 
Follicular adenoma 
 
4 
 
6% 
Benign nodular goiter 2 
 
3% 
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Ultrasonography of thyroid shows: 
Ultrasonogram  of Thyroid was  done  in Seventy  patients in this study  
observations shows:42%  cases of  Grave’s disease, 25% cases of  Multi nodular 
goiter, only 3% cases of Solitary nodules of Thyroid gland. 
 
0
5
10
15
20
25
30
35
40
45
GD MNG SN
No. of Cases
 
Figure 11: Ultrasonogram findings. 
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Correlation of Cardiac findings with Etiology shows: 
Cardiac Symptoms and etiology shows: 
 
Table 16  shows: Cardiac symptoms and etiology shows: 
 
Etiology No of patients 
with cardiac 
symptoms 
Percentage 
Grave’s disease (n=42) 35/42 83% 
MNG (n=25) 16/25 64% 
Solitary Nodule (n=3) 1/3 34% 
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Figure 12: Physical signs and etiology. 
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Table 17 shows: Physical signs and etiology of this study shows: 
 
 
Etiology 
 
Tachycardia 
 
Atrial 
fibrillation 
 
Systolic 
hypertension 
 
Wide pulse 
pressure 
(>60) 
 
Grave’s 
disease 
 
80% 
 
30% 
 
58% 
 
46% 
 
MNG 
 
60% 
 
10% 
 
26% 
 
22% 
 
Solitary 
nodule 
 
20% 
 
0% 
 
0% 
 
0% 
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Cardiovascular abnormalities and etiology of this study shows: 
 
Table  18 shows: Cardiovascular findings and etiology: 
Cardiac signs Grave’s 
(n=42) 
MNG 
(n=25) 
Solitary 
nodule 
(n=3) 
 
Loud S1 
 
14(34% 
 
6(24%) 
 
- 
Ejection 
systolic 
murmur 
(pulmonary) 
 
9(21.4% 
 
2(8%) 
 
1(8%) 
 
Cardiac Failure 
 
8(60%) 
 
2(40%) 
 
- 
Pansytolic 
murmur 
(mitral) 
 
6(14.2%) 
 
2(8%) 
 
- 
Early diastolic 
murmur 
(aortic) 
 
3(7.14%) 
 
1(4%) 
 
- 
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 Table 19  shows: ECG findings and etiology: 
 
ECG finding 
Grave’s 
 
(n=42) 
MNG 
(n=25) 
Solitary 
nodule 
(n=3) 
 
Tachycardia 
 
36(85.7%) 
 
19(76%) 
 
1(33.3%) 
 
Atrial 
fibrillation 
 
8(19%) 
 
4(8%) 
 
- 
 
LVH 
 
7(17%) 
 
2(8%) 
 
- 
 
Chest X-ray PA view   showed cardiomegaly in17% cases of grave’s 
disease (7/42) and 8% case of Multi nodular goiter ( 2/25). 
 
Echocardiographic abnormalities and etiology shows: 
 
Echocardiographic    findings    were   observed   in   66.6% (28/42) 
patients of grave’s disease,   40% (10/25) cases of Multi nodular goiter, 33.3% 
(1/4) patients  of solitary nodule. 
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Table 20 shows:  Echo findings and etiology: 
 
Echo findings Grave’s 
disease 
(n=42) 
MNG 
(n=25) 
Solitary nodule 
(n=3) 
 
Diastolic dysfunction 
 
16(38%) 
 
3(12%) 
 
1(33.3%) 
Mitral regurgitation  
9(21.4%) 
 
1(4%) 
 
- 
Pulmonary 
hypertension 
 
3(4.76%) 
 
1(4%) 
 
- 
 
Aortic regurgitation 
 
3(7.14%) 
 
- 
 
- 
Tricuspid 
regurgitation 
 
3(7.14%) 
 
- 
 
- 
 
Mitral valve prolapse 
 
 
2(4.76%) 
 
- 
 
- 
 
Left ventricular 
hypertrophy 
 
7(17%) 
 
2(8%) 
 
- 
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Correlating the etiology and clinical symptoms and signs and 
investigations, it was   observed    that atrial fibrillation was significantly 
associated with Grave’s disease (p value<0.05). However if p value more than 
0.05 statistically it is not significant. In Grave’s disease patients had more 
systolic hypertension and   wide pulse pressure of more than 60 mmHg was 
seen in  47.6% patients with Grave’s compared to 20% of patients with Multi 
nodular goiter.  Hence   patients with Grave’s disease   had severe disease than 
other causes of hyperthyroidism and Thyrotoxicosis. 
Correlation of cardiac abnormalities with thyroid function tests 
and severity of hyperthyroidism of this study shows: 
The   observations    were   statistically    analyzed    using   ‘ Pearson 
Chi-square” test to find out the correlation  between cardiac abnormal 
symptoms and   signs and    thyroid hormone   levels. For convenience, T3, T4 
and TSH levels were further subdivided in to   arbitrarily. 
 
T3 <200 (ng/dl)                T4 12-17 (mcg/dl)          TSH   <0.009 (mU/ml) 
200-399                      18-23                                    0.01-0.09 
     400-599                                  24-30                                    >0.1 
     600-799                                    >30 
      >800 
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 T3, T4 and TSH levels were compared with cardiac symptoms 
Palpitations, Tachycardia, Atrial fibrillation, Hypertension, Wide pulse 
pressure, Cardiac signs, , Chest X-ray PA view, ECG and Echocardiographic  
findings. 
Statistically accurate  correlation  observed between thyroid hormone 
levels (severity of hyperthyroidism) and cardiac symptoms and signs, heart rate, 
pulse pressure, , chest X-ray PA view, ECG and Echocardiographic findings  
(Pvalue less than 0.05). 
Hence, the severity hyperthyroidism disease correlated with atrial 
fibrillation in this study. High T3 with low TSH levels correlated with the 
presence of atrial fibrillation (p values 0.028 and 0.0669respectively). T4   
levels   were correlated significantly with atrial fibrillation (p value 0.062). High 
T4 levels and low TSH levels were significantly correlated with the presence of 
systolic hypertension (p values 0.06 and 0.08 respectively) in this study. T3 
levels   correlate with presence of systolic hypertension (p value 0.060). 
Grave’s disease was found to have severe disease associated with high 
(T3, T4 levels and low TSH levels) as compared to Multi nodular goiter and 
solitary nodule. The p values correlating T3, T4 and TSH with Grave’s   disease  
were  0.06,0.07 and 0.042 respectively observed in this study. 
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Correlation of cardiac abnormalities with age of this study shows: 
Table 21  shows: Cardiac symptoms & signs   and age shows: 
 
Age (Years) 
Cardiac 
Sympto
ms 
Tachycardia Atrial 
Fibrillation 
Systolic 
hypertension 
Wide  
Pulse 
pressure 
<20years(noof 
cases-2) 
1 0 0 0 0 
20-29 years(no of 
cases-6) 
 
2 
 
2 
 
1 
 
3 
 
2 
30-39years (no of 
cases-24) 
22 23 5 10 10 
40-49 years (no of 
cases-20) 
 
18 
 
19 
 
4 
 
8 
 
8 
50-59years (no of 
cases-9) 
 
6 
 
5 
 
1 
 
7 
 
2 
60-69years (no of 
cases-6) 
 
4 
 
5 
 
1 
 
6 
 
2 
>70years(noof 
cases-3) 
 
2 
 
2 
 
0 
 
0 
 
1 
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Table  22  shows:  Cardiac abnormalities and age shows: 
 
 
 
Age (Years) 
ECG 
abnormalities 
CXR 
abnormalities 
Echo 
abnormalities 
<20 years (no 
of cases-2) 
 
1 
 
0 
 
0 
20-29years  (no 
of cases-6) 
 
2 
 
1 
 
2 
30 -39 years  
(no of cases - 
24) 
 
22 
 
7 
 
15 
40-49years  
(noof cases-20) 
 
19 
 
4 
 
10 
50-59years  (no 
of cases-9) 
 
7 
 
1 
 
6 
60-69years  (no 
of cases-6) 
 
3 
 
1 
 
5 
>70 years (no 
of cases-3) 
 
2 
 
0 
 
1 
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A correlation was noted between atrial fibrillation and age between 30 to 
49 years (p<0.05). Other cardiac abnormalities also associated with  significant  
association  with  age. 
Treatment: 
All patients were treated with antithyroid drugs. Carbimazole was given 
for 46 patients. Eight patients received propylthiouracil. Two patients received 
both carbimazole and propylthiouracil in view of severe disease. All patients 
except two patients with bronchial asthma received propranolol. That patient 
was given verapamil. Carbimazole with Digoxin given for five cases. 
Carbimazole with Lasix given for seven cases. Seventy patients were initially 
treated with drugs alone. Patients whom refractory to medical treatment 
underwent surgical treatment. Out of these Seventy cases, (20/70) Twenty 
patients underwent surgery. Twelve cases of GD underwent Total 
thyroidectomy. Seven patients of MNG underwent subtotal thyroidectomy and 
One patients of solitary nodule underwent  hemi thyroidectomy.  
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Table 23  shows:  Treatment Profile to Control cardiac signs and 
symptoms: 
Treatment No of patients Percentage 
Drugs alone 50 71.42% 
Surgery 20 28.57% 
 
 
 
Table 24 shows:  Drug Profile of this study shows: 
 
Drugs No of 
patients 
Carbimazole, propranolol 46 
Carbimazole, propranolol, lasix 7 
Propylthiouracil, propranolol 4 
Propylthiouracil, propranolol, lasix 4 
Carbimazole, propranolol, digoxin 5 
Carbimazole,propranolol, 
propylthiouracil 
2 
Carbimazole, verapamil, 
propylthiouracil 
2 
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Follow up: 
The patients were followed up and re-evaluated after 6 months. Two 
patients was expired of cardiac failure during the follow up period and   Sixty 
eight patients were   reevaluated after six months. 
Follow up cardiac symptoms after six months: 
On follow up, out of the Sixty eight patients only six patients (9%) had 
persisting cardiac symptoms, in the form of palpitations. Edema  presented  in 
Two patients. 
Follow up cardiac signs after six months shows: 
Table   25 shows: Follow up Cardiac signs after six months shows: 
Physical sign No of patients Percentage 
Tachycardia 4 6% 
Systolic hypertension 1 1.47% 
Atrial fibrillation 1 1.47% 
The mean heart rate on follow up was 86/min. Tachycardia was present in 
6% of cases. 1.47% patients had hypertension and1.47% patients had atrial 
fibrillation. 
On follow up, one patient (1.47%) had loud S1, one patient (1.47%) had 
ejection systolic murmur, two patients (2.94%) had pansystolic murmur and two 
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patients (2.94%) had early diastolic murmur.  One of the patients had cardiac 
failure on follow up. 
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symptoms Tachycardia SHT AF
No of cases Followup cases
Figure 13: Comparison between  baseline and follow up cases of 
cardiac symptoms and signs. 
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Follow up thyroid profile after six months shows: 
Eight patients (12%) had mild hyperthyroidism on follow up. On follow 
up mean T3 was 172.8ng/dl, mean T4 was 09.26mcg/dl and mean TSH was  
0.928  micro unit /ml. 
Follow up ECG after six months of this study shows: 
Ten percent patients had ECG abnormalities on follow up. LVH persisted 
in eight follow up   patients .Out of these twelve patients with atrial fibrillation, 
in Eleven patients sinus rhythm was achieved.  One patient had persistent atrial 
fibrillation. 
Follow up Chest X-ray after six months shows: 
6% percent (4/68) patients had cardiomegaly on follow up 
Follow up Echocardiography after six months shows: 
With regular treatment, on follow up there was reduction in the 
echocardiographic abnormalities. The mean ejection fraction on follow up was 
64.04%. 
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Table 26 shows: Follow up Echocardiography after six months 
shows: 
 
 
Abnormality 
 
No of Patients 
 
Percentage 
Diastolic dysfunction 4 6% 
Mitral regurgitation 2 3% 
Left ventricular 
hypertrophy 
8 12% 
Pulmonary hypertension 1 3% 
Aortic regurgitation 1 3% 
Tricuspid regurgitation 0 - 
Mitral valve prolapsed 1 3% 
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Treatment modality and response to treatment shows: 
The response to treatment as assessed by resolution of symptoms and 
signs, improvement in thyroid profile and improvement or resolution of ECG, 
Chest X-ray and echocardiographic abnormalities-in the  treatment groups were 
statistically analyzed and compared using Chi-square test. Statistically 
correlation observed the treatment cases (p<0.05). To conclude, no treatment 
modality was superior over the other and response to treatment is not dependent 
on the treatment modality adopted. 
Data was obtained and   analyzed to find whether, response to treatment 
and treatment outcomes have any correlation with etiology of hyperthyroidism. 
Statistically significant correlation was noted between etiology of 
hyperthyroidism and treatment outcome (p<0.05). 
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DISCUSSION: 
A descriptive, prospective study about cardiac manifestations of 
hyperthyroidism was conducted among 70 consecutive patients of 
hyperthyroidism, thyrotoxicosis attending medical OPD or admitted in medicine 
wards, Department of Internal Medicine, Thanjavur Medical College and 
Hospital, Thanjavur during the period from October 2011- November 2012.The 
data was obtained and analyzed statistical correlation using Pearson’s Chi-
square test”. 
Age Distribution: 
The mean age of presentation was 42.08years. 63% of patients were 
between 30 and 49 years. 60% of cases with GD and 36% of cases with MNG 
the age between 30 and49 years. This is comparable with the existing literature 
showing common occurrence of Grave’s disease in the 20-50 age group1  .All 
patients with solitary nodule were between 30 and 49years.age <20 years age 
patient had Grave’s disease. Patients were age more than 70 years had Multi   
nodular goiter. 
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Sex Distribution:  
Females were more affected than males in the current study. This is 
consistent with available literature
1,77.
 The male: female ratio in this study was 
1:6. The male: female ratio was 1:9.5, 1:4 and 1:2 in patients with Grave’s 
disease, Multi nodular goiter and toxic adenoma respectively. A higher 
proportion of males were noted in this study.  Literature shows a male: female 
ratio of 1:10 in patients with Grave’s disease1.   
Modes of Presentation: 
Heat intolerance, fatigue, Diarrhea and weight loss were the other 
commonest presenting symptoms noted in this study.  
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Table27shows: Comparison of presenting symptoms in 
hyperthyroidism: 
 
 Symptom Present study 
(%) 
Bhadada S et al 
78
(%) 
Weight loss 50% 82.1 
Heat intolerance 69% 76.8 
Increased appetite 29% 73.2 
Diarrhea 17% 48.2 
 
Neurological abnormalities were seen in 65% cases. Tremor was the 
commonest neurological sign (51%), followed by hyperreflexia (23%). 
However, only 11% patients observed tremor as a presenting symptom in our 
study. 
Thyroid ophthalmopathy was observed in 50% cases in our study. Among 
Grave’s disease patients, 80% had ophthalmopathy, comparable to the existing 
literature showing ophthalmopathy in 75% cases 
1
.We noticed a slightly higher 
incidence of dermopathy (12%) as compared to the reported 5%
1 
. 
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Cardiac symptoms, signs and abnormalities: 
Palpitation was observed as a commonest cardiac symptom in our study, 
which was well correlate with the available literature   
41,42,43  
. In our study, 79% 
patients had cardiac symptoms on presentation. 
80% of our cases had tachycardia, 17% had atrial fibrillation and 49% had 
systolic hypertension. A wide pulse pressure was noted in 36% cases. As per the 
literature,   In hyperthyroidism  tachycardia is the commonest cardiac sign. In 
this study shows 17% of cases had AF, which was comparable with the reported 
prevalence of 2-20% 
41,49,50.
 
Cardiovascular system examination showed abnormalities in 67% cases, 
the commonest being a loud S1.Among the murmurs presentation Pulmonary 
ejection systolic murmur due to  hyper dynamic circulation was the commonest 
one, seen in 17%  of patients.14.2 % of patients had cardiac failure. 
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Table 28 shows: Comparison of cardiac symptoms and signs 
shows: 
 
Cardiac abnormal 
features 
In our study 
(%) 
Klein et al
43 
(%) 
Palpitations 79% 85% 
Tachycardia 80% 95% 
Atrial fibrillation 17% 15% 
Wide pulse pressure 36% 75% 
Cardiac murmurs 34% 50% 
Edema 14% 05% 
Electrocardiogram abnormalities were seen in 80% cases, tachycardia being the 
commonest abnormality observed in our study.  AF was   observed in 17% of 
cases. Cardiomegaly was observed in chest X-ray PA view 14% of patients. 
Echocardiographic abnormalities were noted in 56%   of patients. Diastolic 
dysfunction was noted in 29% of patients.  Valvular   involvement  were  noted  
in our study.  Among the   observations of the   valvular abnormalities, mitral 
regurgitation was the commonest one. Diastolic dysfunction was common in 
patients above 40 years and 42.4% of patients with diastolic dysfunction had 
associated hypertension. Advanced age   of the patient and hypertension are risk 
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factors for diastolic dysfunction. However none of the patients less than 40 
years of age with diastolic dysfunction (8/20) had hypertension. Also 30% of 
our subjects of less than 40 years had diastolic dysfunction compared to the 
normal prevalence of 2-4% in the age group of   25-35 years. Hence the younger 
age groups of hyperthyroidism, thyrotoxicosis   patients is an independent risk 
factor for diastolic dysfunction observed in our study. LAE was noted in 46% 
(5/12) cases have Atrial fibrillation. All patients with left atrial enlargement the 
age group between 30- 60 years of age. In a previous study analyzing the 
relationship between LAE
 
with Atrial fibrillation in hyperthyroidism, left atrial 
enlargement existed in 9% of patients
 
younger than 40 years of age. 
Table  29 shows: Comparison of cardiac abnormalities: 
Cardiac 
abnormalities 
Present Study De Carvalho filho et 
al
75
 
Symptoms 80% 70.9% 
ECG abnormalities 80% 83.3% 
Tachycardia 66.6% 62.5% 
Atrial fibrillation 17% 33.3% 
Cardiomegaly 22.2% 64.7% 
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Electrocardiogram abnormalities observed in our study was comparable 
with the available   literature 
40,41,61
. We   observed  less cardiomegaly and atrial 
fibrillation. This may be due to the fact that we had less number of elderly 
patients in this study.
49,50
 Embolic episodes were noted in one of our patients. 
Etiological Profile: 
Grave’s disease was the commonest cause of hyperthyroidism in our 
study. 60% of our cases of hyperthyroidism were due to Grave’s disease. This is 
slightly less compared to the reported incidence of 60-80%
1
.We had only very 
few cases of toxic adenoma. Since the numbers patients small study group and 
this is a Medical college and   hospital-based study, it is not appropriate to 
comment based on this study report. 
Correlation of cardiac abnormalities with age, severity of disease 
and etiology: 
Atrial fibrillation was common in even younger patients with 
hyperthyroidism compare than older patients.80% of patients with atrial 
fibrillation were age between 30-60 years. In the age group above 60 years, less 
number of patients (20%) had atrial fibrillation. Atrial fibrillation is 
significantly more common in younger patients observed in our study. 
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This study, we observed that patients with severe disease had higher 
incidence of atrial fibrillation and systolic hypertension. Also it was observed 
that patients with Grave’s disease had severe disease as compared to 
hyperthyroidism due to other causes. Age and severity of disease were the 
important cause for AF  in hyperthyroidism. 
Grave’s disease patients had an increase incidence of AF. 80 % cases of atrial 
fibrillation had  Grave’s disease. Patients with Grave’s disease associated with 
younger
 
age, have an increased prevalence rate of Atrial fibrillation .In a 
previous study state that prevalence of atrial fibrillation was only 43% whereas 
it was only 10% in patients with Graves’ disease51. Grave’s disease patients also 
had more systolic hypertension as compared to other etiologies. However, 
Grave’s disease patients were of younger age and had more severe disease. 
Wide pulse pressure was noted more commonly in patients of Grave’s disease. 
Hence   this study   reflects of severity of   disease in Grave’s disease patients. 
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Response to treatment of this study shows: 
Therapeutic strategies   followed   in this study included drugs and 
surgery. Two   patients   were   expired during the follow up due to refractory 
cardiac failure. Sixty eight   patients were reevaluated after six months.  
Table30shows: Cardiac abnormalities before and after treatment: 
 Cardiac abnormality At 
presentation 
On follow 
up 
Palpitation 79% 5% 
Tachycardia 66.6% 8% 
Atrial fibrillation 17% 2% 
Systolic hypertension 49% 3% 
Loud S1 29% 2% 
Ejection systolic murmur 17% 3% 
Pansystolic murmur 11% 2% 
Cardiac failure 14.2% 0% 
Cardiomegaly 22.2% 16% 
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At follow up only 4% had cardiac symptoms compared to the 80% on 
presentation. Edema subsided with treatment in all follow up   cases. 
With treatment there was significant reduction in cardiac mortality and 
morbidity. Only one patient had persistent atrial fibrillation on follow up.  
Patients age above 50 years old and had gross left atrial enlargement. Treatment 
of hyperthyroidism is frequently associated with reversal
 
of atrial fibrillation to 
sinus rhythm.  
On treatment, there was significant reduction in   symptoms and signs of 
tachycardia, palpitation, atrial fibrillation, systolic hypertension and other 
cardiac abnormalities. Cardiac failure improved in all the patients with regular 
treatment and follow up. Left ventricular hypertrophy was persisted in follow up  
patients with cardiac failure  inspite of the regular treatment. 
Six patients had mild hyperthyroidism on follow up. There was 
significant Echocardiogram findings   reversal   on follow up with treatment.  In 
this study revealed Diastolic dysfunction improvement was   shown in patients 
with hyperthyroidism on early diagnosis, regular treatment and follow up  
period of  six months . Left atrial enlargement persisted in two  cases  inspite  of  
the  regular treatment and follow up. 
 
 
  
79 
 
Table 31 shows:  Echo findings before and after treatment shows: 
Abnormality At Presentation 
(%) 
On follow up 
(%) 
Diastolic dysfunction 29% 8% 
Mitral regurgitation 14% 3% 
Left ventricular 
hypertrophy 
13% 6% 
Pulmonary hypertension 9% 3% 
Aortic regurgitation 7.14% 2% 
Tricuspid regurgitation 7.14% 2% 
Mitral valve prolapse 4.76% 2% 
 
Treatment of hyperthyroidism reversed cardiac symptoms signs observed  
in majority of  study group patients .In a previous study reveals that  of 356 
patients with cardiac involvement with atrial fibrillation, angina or cardiac  
failure, over 90% had improvement in cardiac symptoms and signs after 
adequate treatment
72       
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Statistically significant correlation was noted between etiology of 
hyperthyroidism and treatment outcome. However, the numbers of patients of 
the study   were   small to comment on   significant conclusions in this study. 
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Limitations of the study: 
This is a Medical college and hospital based study conducted in a   
tertiary care   center   and   is not so much   informative   of the patterns  of the 
disease involving  in the community. The study population was   minimal only   
seventy cases .  Larger community based studies are needed in   future   to find 
out the exact   incidence and prevalence of cardiac   symptoms and signs 
associated with hyperthyroidism   and   the clinical epidemiological patterns of 
hyperthyroidism in our region.  
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SUMMARY AND CONCLUSIONS: 
 Majority of the patients with hyperthyroidism were between 30 and 49 
years old (63%). Mean age was 42.08 years. Majority of younger patients 
with Grave’s disease and younger and elderly patients with 
hyperthyroidism had Multi nodular goiter. 
 The patients were observed in this study   predominantly females. The 
male: female ratio was 1:6. 
 Palpitation was the most commonest cardiac symptom in hyperthyroidism 
(79%). Tachycardia (80%) was the most common cardiac sign observed 
in this study. Atrial fibrillation was noted   in 17% of patients.  
 The other commonest presenting symptoms were heat intolerance , 
fatigue, increased appetite and weight loss observed in this study. 
 Electrocardiogram abnormalities were noted in three fourth of patients in 
this study (80%), tachycardia being the commonest sign observed in this 
study. One fourth (20%) of patents had cardiomegaly and nearly more 
than half of the   patients ( 56 %) had   echocardiographic   significant 
cardiac findings.  Hyperthyroidism   is   one of the commonest   risk 
factor for diastolic dysfunction in young patients noted in this study.  
Valvular abnormalities also common but rare observed in this study. 
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Among all the Cardiac valvular abnormalities, Mitral regurgitation  and 
Mitral valve prolapse  was the commonest one. 
 Grave’s disease was the commonest causes of hyperthyroidism, 
thyrotoxicosis   contribute about   60% of cases. 
 Atrial fibrillation was common in young and elderly   patients with 
hyperthyroidism noted in this study. 70% of patients with atrial 
fibrillation were observed   in the age of 30- 60 years   of age group in 
this study. 
 High Triiodothyronine and low TSH levels correlated well with the 
presence of atrial fibrillation in this study. High Thyroxine levels and low 
TSH levels were significantly associated with   systolic hypertension. 
 Age and severity of the disease are the most important risk factors for 
atrial fibrillation in hyperthyroidism in this study. 
 Patients with Grave’s disease had severe disease   than   hyperthyroidism 
due to other causes like   Multi nodular goiter and toxic adenoma noted in 
this study. 
 Grave’s disease   patients had a higher prevalence of atrial fibrillation. 
80% of patients with atrial fibrillation had Grave’s disease. 
 Treatment of hyperthyroidism improves the cardiac symptoms and signs 
in most of the patients observed in this study. There was significant 
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improvement   noted in clinically as well as in the ECG and ECHO   
findings   with treatment. Younger patients with atrial fibrillation had 
higher chance of reversal to sinus rhythm observed in this study. Cardiac 
failure improved with treatment in all patients participated in this study 
group.  
 Treatment strategy and etiology of hyperthyroidism definitely have   
impact on   well response to treatment noted in this study group. 
 
 
 
 
 
 
 
 
PROFORMA 
 
Name                                                    Age                 Sex                                                              
Education                                             Occupation         
Marital status                                       OP/IP No:                         DOA: 
Duration of symptoms                                                                  DOD: 
 
Presenting symptoms 
Hyper activity 
Heat intolerance & sweating 
Irritability 
Palpitation & chest discomfort 
Fatigue 
Loss of weight 
Excessive  appetite 
Passing loose stools 
Polyuria 
Oligomenorrhoea 
Loss of libido 
Infertility 
Impaired concentration 
History of fracture 
Others if any 
Previous Illnesses 
Clinical Examination: 
General examination  
Height                                     Weight                                  BMI 
Pulse rate                                AF +/- 
Blood pressure                        Pulse pressure 
Pallor                                      Icterus 
Skin--- warm / moist 
          
    Dermopathy 
             Pretibial myxedema 
             Palmar erythema 
             Urticaria 
             Hyperpigmentation            
Lymphnode                                                                
Goitre     
   Thrill / bruit  
   Ophthalmopathy 
Systemic Examination 
CVS   
P/A 
Respiratory system                                                                       
CNS   hyper reflexia      
           Muscle wasting 
           Proximal myopathy      
  Investigations            
LFT 
Complete blood picture 
Urine routine: 
RFT 
RBS 
Electrolytes 
TFT 
T3:                            T4:                           TSH: 
Lipid profile 
Sr. Calcium:                
Sr. Phosphorus:  
ECG:  
Chest X-ray: 
Echocardiogram: 
FNAC Thyroid: 
 
USG  Neck: 
Any other relevant investigations 
Etiology 
Treatment given: 
Follow up after 6 months 
Follow up symptoms 
HR      BP 
AF +/-         
Systemic Examination                                  
TFT 
T3:                     T4:                          TSH: 
ECG 
CXR 
Echo: 
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1 Valli 40 F 1320450 P p P P P P N N N P P N P P N N N 8 154 48 20.25 N N 100 N N N N 130/80 50 N N N N 11.6 100 N N N N N 52% N GD
2 Vijaya 42 F 1320550 p N p p p N p N p N N N N N M p 6 148 42 21.2 P P 102 IRR N N N 136/72 58 N N N N 12 228 15 0.1 430 1.88 N 120 IRR N AF N N 56% N GD
3 Geetha 36 F 1321202 P N N N N N N N N N N P P P P N N 6 152 45 20.6 P N 90 N N N N 128/8O 48 N N N N 10.5 246 19 0.08 440 2.2 CM 110 N N N N P 58% N MNG
4 sudha 40 1321407 P N N P P P N P N N N N N N N M N 20 156 46 22.6 P N 92 N H N N 140/86 64 N N N N 11 236 20 0.09 420 1.6 N 94 N N N N N 54% N GD
5 Uma 18 F 1322567 P P N N N P N N N P N N N N N N P 12 160 52 23.4 N N 96 N N N N 150/84 66 R P N N 12 212 24 0.06 416 1.8 CM 96 N N N N P 52% N GD
6 Lakshmi 39 F 1322834 P N N N P P N P N N P N P P P M N 12 164 47 21.8 P P 100 N N N N 150/92 58 N N N N 11 198 22 0.2 423 2 N 106 IRR N AF P P 48% P MNG
7 Kamatchi 52 F 1323783 P N P N N P N N N N N N N N N N N 8 173 48 20.9 P N 88 N N N N 160/96 64 R N N N 9.5 210 18 0.04 410 2.2 N 108 N ST N N N 46% P GD
8 somu 40 M 1324356 P N N N N P P N P N P N N N M N 6 162 50 23.4 N N 102 IRR N N THICK 170/108 62 N N P ABN 10 310 16.5 0.06 412 1.8 N 112 IRR N AF P N 56% N GD
9 Selvi 42 F 1324902 P N N P N P N P N N N N N N N N P 7 146 51 22.8 P N 104 N H N N 150/80 70 N P N N 11 432 17.5 0.08 402 2.2 CM 128 N N N N N 54% N MNG
10 Vasuki 30 F 1325197 P N N N N P N N N N N N N P P M N 9 150 52 19.8 N N 90 N N N N 140/82 58 N N N N 12 380 21 0.04 403 2.82 N 112 N N N N N 54% N GD
11 Devika 33 F 1325265 P P P P P P N P N P P P N N N N N 6 148 49 19.4 P N 100 N N N N 156/94 62 R N P N 13 440 19.2 0.02 443 1.96 N 98 N N N N N 44% P GD
12 Radhika 37 F 1325467 P N N N N N N N N N N N N N N N P 12 154 44 20.8 N N 94 N N N N 142/86 56 N N N N 14 420 18.5 0.05 462 1.98 N 96 IRR N AF P P 61% N MNG
13 Dhanalakshmi 44 F 1325786 P N N P P P N P P P N N N N N M N 10 144 41 19.8 P P 96 N H N N 150/90 60 N N N N 10 412 20 0.04 456 2.2 CM 94 N N N N N 45% P GD
14 Gayathri 26 F 1326101 P P P P N P N N N N N N N N N N N 4 152 54 20.6 N N 98 N N N N 170/104 66 N N N N 9 330 22 0.02 423 2.4 N 88 IRR N N N N 55% N MNG
15 Akila 39 F 1326308 P N N N N P P P N P P P P N P M N 5 164 48 21.6 P N 86 N N N N 146/82 64 R N N N 8 280 24 0.09 472 2.32 N 106 N N N N N 53% N GD
16 Jeyanthi 31 F 1326709 P N N P P N N N N N N N N N N N N 6 147 46 19.8 N N 102 N H N N 160/104 54 N N N N 10 360 22 0.06 480 2 CM 102 IRR N AF N P 54% N GD
17 Reguna 19 F 1327009 P P N P P P N P N N N N N P N M N 6 145 47 18.8 P N 106 IRR N IRR N 170/120 50 N P P ABN 9.2 340 23.5 0.09 468 1.84 N 104 IRR ST N N N 58% N MNG
18 Mariammal 54 F 1327187 P N N N N P N P N P N N N N N N P 12 161 51 20.6 N N 90 N N N N 180/118 62 N N P N 8.8 312 20 0.3 458 1.92 N 100 N N N N N 54% N GD
19 selvarani 42 F 1327386 N N P P N N N N N N P N N N M N 11 160 50 21.8 P N 92 N N N N 170/110 60 N P N N 9.2 417 21 0.04 486 1.86 N 98 N N N N N 52% N MNG
20 Geetha 28 F 1328079 P P P P P P N P N N N N P N P N N 12 150 45 20.4 N N 94 N H N N 140/86 54 N N N N 9.6 425 16.7 0.07 486 1.85 CM 96 N N N N N 58% N SN
21 Selvam 42 M 1328111 P N N N N P P N N P P N N N N M N 7 172 46 22.4 p P 96 N N N N 150/96 54 R N N N 10.8 432 18.4 0.06 444 2.2 N 116 IRR N AF P P 48% P GD
22 kathirvel 56 M 1328514 N N N N P N P N N N P N N N N P 8 149 60 21.8 N N 100 N H N N 160/104 56 N N N N 11 467 19 0.04 452 2.6 N 104 N N N N N 50% N GD
23 Sathya 43 F 1328712 P p P P P P N N N P N N P P P M N 6 148 58 22.4 P N 98 N N N N 160/100 60 R N N N 10 322 20 0.06 428 1.76 N 108 IRR N N N N 52% N MNG
24 Rengammal 52 F 1329007 P N N P P N N P N N N N N N N N 9 153 48 21.6 N N 102 N H N N 130/82 48 N N N N 12 352 21 0.05 456 1.68 N 116 N N N N N 60% N GD
25 Muthulakshmi 38 F 1329516 P N N N N P N N N P P P P N N M N 10 152 54 21.8 P N 96 N N N N 150/104 46 R P N N 13 510 21.5 0.01 442 2.3 N 120 IRR ST AF N N 54% N GD
26 Veerama 62 F 1330189 P P P P P N P P N N N N N N N N N 12 154 46 22.6 N N 100 N H N N 152/100 52 N N N N 12 342 16 0.02 440 2.5 N 114 N N N N N 52% N MNG
27 Angammal 65 F 1331213 P N N P P P N N N P N N N N N M N 8 146 44 19.6 P N 102 N N N N 170/114 56 N N N N 13 296 17 0.02 421 2.1 N 118 IRR N AF N N 56% N SN
28 Meenakshi 47 F 1332796 P N N N N N N P N N N P P N P N P 6 148 46 19.2 N N 105 IRR N IRR THICK 150/96 54 N N P N 14 386 18 0.03 426 2.3 N 96 N N N N N 42% P GD
29 Kamalambal 62 F 1333465 P N N N P P P N N N N N N N N M N 6 153 50 21.6 N N 90 N N N N 160/102 58 N N N N 10 388 20 0.03 432 2.2 CM 108 IRR N AF N P 48% P GD
30 karthika 29 F 1333902 P P P P P N N P N P P P N N N N N 8 143 52 21.6 P P 92 N N N N 170/110 60 N P N N 12 402 16.3 0.02 452 1.88 N 98 N N N N N 52% N MNG
31 Maheswari 38 F 1334532 P P N N N P N N N N N N N P P M N 8 153 60 22.6 N N 94 N N N N 130/68 62 R N N N 11 428 17.8 0.01 478 1.67 N 108 N N N N N 49% P GD
32 Amsavalli 48 F 1335209 P N N P P N P P N N N P N N N P 7 151 62 21.8 P N 96 N H N N 120/68 52 N N N N 12 376 20 0.02 450 1.86 N 110 N ST N N N 50% N GD
33 Saranya 31 F 1336882 N N P N N N N N P P N P N N M N 7 148 56 22 N N 98 N N N N 140/86 54 N N P N 9.5 350 21 0.02 468 1.86 CM 100 N N N N P 54% N MNG
34 Shobana 36 F 1337381 P N N N P P N P N N N N N N N N N 12 156 54 23.2 P P 100 N N N N 130/76 54 N N N N 11 334 22 0.04 438 2.22 N 116 IRR N AF P N 52% N GD
35 Sumathi 39 F 1337846 P P P N N P N N N N N P N N N M N 10 153 52 22.4 N N 102 N N N N 130/70 60 N N N N 10 434 24 0.02 430 2.6 N 102 N N N N N 50% N GD
36 Chellapan 53 M 1338145 P N N P P N N P N P P N P P P M N 11 152 50 23.6 P N 98 N N N N 150/92 62 R P N ABN 8.6 412 20 0.04 426 2.2 N 104 IRR N AF N N 52% N MNG
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40 Hema 33 F 1341627 P N N N N N N P N N N N N N N M N 3 154 48 22.4 N N 98 N N N N 150/90 60 N N N N 13.2 520 16.8 0.04 464 1.8 N 96 N ST N N N 45% P GD
41 Saroja 52 F 1342555 P N N P P P N N N P N P N N N N P 6 144 51 21.8 P N 102 N N N N 144/92 52 N N N N 14 324 18 0.02 452 2.2 N 94 N N N N N 46% P GD
42 Nasrin fathima 28 F 1343689 P P N N P N P N N N N N P P M N 7 149 49 20.6 N N 96 N H N N 130/76 54 N N N N 12 346 19 0.04 476 2.3 N 92 IRR N AF P P 52% N GD
43 Govidammal 60 F 1344244 P N N N N N P N N P P P P N N M N 7 148 48 20.4 P P 98 N N N N 120/64 56 N N N N 11 356 19 0.02 380 2.1 N 88 N N N N N 54% N MNG
44 Mala 42 F 1344029 N N P P P N P N N N N N N N N N 8 150 50 23.2 N N 88 N N N N 166/104 62 N P P N 12.4 364 20 0.04 390 2 N 90 N N N N N 52% N GD
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46 Ilakkaiyan 47 M 1345351 P N N P P P N N N P N P N N N M N 12 154 44 22.2 N N 102 N N N N 140/76 64 N N N N 10.8 298 22 0.02 404 2.2 N 104 N N N N N 40% P GD
47 Pushpavalli 38 F 1346761 P N N N N N N P N N N N P P P M N 10 166 47 21.6 P N 98 N N N N 150/82 68 N N N N 11 344 23 0.01 462 2.4 N 106 N N N N P 47% N GD
48 Tamilmani 36 F 1347625 P P P P P P P N N P N N N N N N P 9 166 45 22.2 N N 96 N N N N 162/100 62 N N N N 12 326 21 0.02 452 2.6 N 108 N N N N P 54% N MNG
49 murugeswari 71 F 1348745 P N N N N P N P N N P P N N N M N 8 159 52 22.6 P N 94 N H N N 150/86 64 N N P N 12 336 20 0.03 428 2.8 CM 102 N ST N N N 60% N GD
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KEY TO MASTER CHART 
ABN-Abnormal  
AF-  Atrial fibrillation 
AR- Aortic regurgitation 
BP- Blood Pressure 
BMI- Body mass index 
CCF – Congestive Cardiac Failure 
CM- Cardiomegaly 
Col.Nod- Colloid nodule 
CVS-Cardio vascular system 
CNS- Central nervous system 
CF- Cardiac failure 
D- DE diffuse enlargement 
D -  Digoxin 
DD- Diastolic dysfunction                                                             
DI- Diarrhea 
ECG – Electrocardiogram 
ECHO - Echocardiogram 
EDM- Early diastolic murmur 
ESM- Ejection systolic murmur 
E- Exophthalmos 
FT3 –Free T3 
FT4 –Free T4 
FNAC – Fine needle Aspiration Cytology 
FC- Follicular cells 
F  - Fatigue 
GD- Grave’s disease 
HR- Heart rate 
H  - Heat intolerance 
Hy -Hyper reflexia 
KI-Potassium iodide 
LAE-Left Atrial enlargement  
LI- Lymphocytic infiltrates 
LV – Left ventricle 
LVH-   Left ventricular hypertrophy 
LFT- Liver function test 
MVP – Mitral valve Prolapse  
MNG-  Multinodular goiter 
MR- Mitral regurgitation 
NSR – Normal Sinus Rhythm 
N- No  
NO- Normal 
NE –Carbimazole 
OPD – Out Patient Department 
O- Oedema 
OL -  Oligomenorrhea 
P/A-  Per Abdomen 
PSM -  Pansystolic murmur 
PAH -Pulmonary hypertension 
PP- Periodic paralysis 
P -Present 
PM - Proximal myopathy 
PT – Propylthiouracil 
RBS- Random blood sugar 
RFT- Renal function test 
R- Retrosternal goiter 
SA node-Sino Atrial node 
SHT – Systemic Hypertension 
SN- Solitary nodule 
S- Surgery 
S1- Loud S1 
SVT – Supraventricular Tachyarrhythmia 
SVR – Systemic vascular resistance 
T3/T4 - Thyroid hormones 
T3 – Triiodothyronine 
T4 – Thyroxine 
TSH – Thyroid Stimulating Hormone 
TFT – Thyroid Function Test 
T - Tremor 
TA- tachycardia 
TR- Tricuspid regurgitation 
WPP-Wide Pulse Pressure 
W - Weight loss 
Y -Yes. 
                                        
 
 
 
BIBLIOGRAPHY 
1. Jameson JL, Weetman AP.Disorders of the thyroid gland –In: Harrison’s     
Principles of   Internal Medicine, 18th edition, vol 2; 2911-2939. 
2. Klein I. Thyroid hormone and cardiovascular system. Am J Med 1990; 
88:631-637. 
3. Fazio S, Palmieri PA, Lombardi   G, Biondi B. Effects of thyroid 
hormone on the cardiovascular system. Recent Progress in Hormone 
Research 2004 59:31-50. 
4. Sandler G, Wilson GM .The nature and prognosis of heart disease in 
thyrotoxicosis.   Q J Med 1959; 28:247–269. 
5. Summers VK, Surtees SJ . Thyrotoxicosis and heart disease. Acta Med 
Scand 1961; 169:661–671. 
6. Glass CK, Holloway JM. Regulation of gene expression by the thyroid 
hormone     receptor. Biochim Biophys Acta 1990; 1032:157-176. 
7. Brent GA, Moore DD, Larsen PR. Thyroid hormone regulation of gene 
expression.Annu Rev Physiol 1991; 53:17-35. 
8. Lazar MA. Thyroid hormone receptors: multiple forms, multiple 
possibilities. Endocr  Rev 1993; 14:184-193. 
9.Yen PM, Darling DS, Carter RL, Forgione M, Umeda PK, Chin WW.     
Triiodothyronine (T3) decreases binding to DNA by T3-receptor homodimers 
but not  receptor-auxiliary protein heterodimers. J Biol Chem 1992; 267:3565-
3568. 
10. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid 
hormone.       Endocr Rev 1993; 14:348-399.  
11. Schueler PA, Schwartz HL, Strait KA, Mariash CN, Oppenheimer JH. 
Binding of        3,5,3'-triiodothyronine (T3) and its analogs to the in vitro 
translational products of c-  erbA protooncogenes: differences in the affinity 
of the alpha and  beta forms for the acetic acid analog and failure of the 
human testis and kidney alpha-2 products to bind T3. Mol Endocrinol 1990; 
4:227-234. 
12. Katz D, Lazar MA. Dominant negative activity of an endogenous thyroid 
hormone receptor variant alpha 2 is due to competition for binding sites on 
target genes. J Biol Chem 1993; 268:20904-20910.  
13. Strait KA, Schwartz HL, Perez-Castillo A, Oppenheimer JH. Relationship 
of c-erbA mRNA content to tissue triiodothyronine nuclear binding 
capacity and function in developing and adult rats. J Biol Chem 1990; 
265:10514-10521.  
14. Bradley DJ, Towle HC, Young WS III. Spatial and temporal expression 
of alpha and beta thyroid hormone receptor mRNAs, including the beta 2-
subtype, in the developing mammalian nervous system. J Neurosci 1992; 
12:2288-2302.  
15. Brent GA. The molecular basis of thyroid hormone action. N Engl J Med 
1994; 331 (13) 847-853. 
16. Dillmann WH. Biochemical basis of thyroid hormone action in the heart. 
Am J Med 1990; 88: 626 –630. 
17. Everts ME, Verhoeven FA, Bezstarosti K et al.  Uptake of thyroid 
hormone in       neonatal rat cardiac myocytes. Endocrinology 1996; 137: 
4235 –4242. 
18. Brenta G, Mutti LA, Schnitman M, et al. Assessment of left ventricular 
diastolic      function by radionuclide ventriculography at rest and 
exercise in subclinical      hypothyroidism, and its response to L-thyroxine 
therapy. Am J Cardiol 2003; 91: 1327 –1330. 
19. Kiss E, Jakab G, Kranias EG, et al. Thyroid hormone induced alteration 
in phospholamban protein expression: regulatory effects on sarcoplasmic 
reticulum       Ca2+ transport and myocardial relaxation. Circ Res 1994; 
75: 245 –251. 
20. Morkin E .Regulation of myosin heavy chain genes in the heart. 
Circulation 1993; 87:  1451 –1460. 
21. Ojamaa K, Klemperer JD, MacGilvray SS, et al. Thyroid hormone and 
hemodynamic regulation of beta-myosin heavy chain promoter in the 
heart. Endocrinology 1996;    137: 802 –808. 
22. Magner J, Clark W, Allenby P. Congestive heart failure and sudden death 
in a young woman with thyrotoxicosis. West J Med 1988; 110: 759 –760. 
23. Ladenson PW, Sherman SI, Boughman RL, et al. Reversible alterations in 
myocardial gene expression in a young man with dilated cardiomyopathy 
and hypothyroidism.    Proc Natl Acad Sci USA 1992; 89: 5251 –5255. 
24. Gick GG, Melikian J, Ismail-Beigi F. Thyroidal enhancement of rat 
myocardial       Na, K-ATPase: preferential expression of alpha 2 activity 
and mRNA abundance.  J Membr Biol 1990; 115: 273 –282. 
25. Davis PJ, Davis FB. Acute cellular actions of thyroid hormone and 
myocardial       function. Ann Thorac Surg 1993; 56(suppl): S16 –S23. 
26. Walker JD, Crawford FA, Kato S, et al. The novel effects of 3,5,3'-
triiodo-L- thyronine on myocyte contractile function and beta-adrenergic 
responsiveness in       dilated cardiomyopathy. J Thorac Cardiovasc Surg 
1994; 108: 672 –679. 
27. Levey GS, Klein I. Catecholamine-thyroid hormone interactions and the       
cardiovascular manifestations of hyperthyroidism. Am J Med 1990; 88: 
642 –646. 
28. Hoit BD, Khoury SF, Shao Y, et al. Effects of thyroid hormone on 
cardiac beta- adrenergic responsiveness in conscious baboons. Circulation 
1997; 96: 592 –598. 
29. Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after 
coronary- artery bypass surgery. N Engl J Med 1995; 333: 1522 –1527. 
30. Napoli R, Biondi B, Guardasole V, et al. Impact of hyperthyroidism and 
its correction on vascular reactivity in humans. Circulation 2001; 104: 
3076 –3080. 
31. Polikar R, Burger AG, Scherrer U, Nicod P .The thyroid and the heart. 
Circulation  1993; 87:1435–1441. 
32. von Olshausen K, Bischoff S, Kahaly G, Mohr-Kahaly S, Erbel R, Beyer 
J, Meyer J .Cardiac arrhythmias and heart rate in hyperthyroidism. Am J 
Cardiol 1989; 63: 930–933. 
33. Klein I, Ojamaa. Thyroid hormone and cardiovascular system. N Engl J 
Med 2001; 334(7): 501-509. 
34. Cacciatori V, Bellavere F, Pezzarossa A, Dellera A, Gemma ML, 
Thomaseth K, Castello R, Moghetti P, Muggeo M. Power spectral 
analysis of heart rate in       hyperthyroidism. J Clin Endocrinol Metab 
1996; 81:2828–2835. 
35. Bilezikian JP, Loeb JN .The influence of hyperthyroidism and 
hypothyroidism on alpha and ß adrenergic receptor systems and 
adrenergic responsiveness. Endocr Rev 1983;4:378–388. 
36. Biondi B, Palmieri PA, Lombardi G, Fazio S. Effects of Thyroid 
Hormone on       Cardiac Function - The Relative importance of heart 
Rate, loading Conditions, and myocardial contractility in the regulation of 
cardiac performance in human    hyperthyroidism. The Journal of Clinical 
Endocrinology & Metabolism 2002; 87(3) 968-974. 
37. Gibson JG, Harris AW. Clinical studies on the blood volume: V. 
Hyperthyroidism and myxedema. J Clin Invest 1939; 18:59–65. 
38. Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327:94–
98. 
39. Williams GH, Lilly LS, Seely EW.The heart in endocrine and nutritional 
disorders- In: Braunwald’s Heart disease-A textbook of cardiovascular 
medicine, 5
th
 edition; vol 2:1887-1913. 
40. Klein I, Levey GS. The cardiovascular system in thyrotoxicosis-In: 
Werner and Ingerbar’s The thyroid, 7th edition; 607-615. 
41. Olshausen KV, Bischoff S, Kahaly G. Cardiac arrhythmias and heart rate 
in      hyperthyroidism. Am J Cardiol 1989; 63:930. 
42. Klein I, Trzepacz P, Roberts M, Levey GS. Symptom rating scale for 
assessing  hyperthyroidism. Arch Intern Med 1988; 148:387. 
43. Featherstone HJ, Stewart DK. Angina in thyrotoxicosis and thyroid 
related coronary  artery spasm. Arch Intern Med 1983; 143: 554. 
44. Klein I, Ojamaa K. Thyrotoxicosis and the heart. Endocrinol Metab Clin 
North Am 1998; 27:51-62. 
45. Nordyke RA, Gilbert Jr FI, Harada AS. Graves’ disease. Influence of age 
on clinical findings. Arch Intern Med 1988; 148:626–631.  
46. Graettinger JS, Muenster JJ, Selverstone LA, et al. A correlation of 
clinical and hemodynamic studies in patients with hyperthyroidism with 
and without congestive heart failure. J Clin Invest 1959; 39: 1316 –1327. 
47. Channick BJ, Aetlin EJ, Marks AD. Hyperthyroidism and mitral valve 
prolapse. N Engl J Med 1981; 305: 497. 
48. Kahaly GH, Dillmann WH. Thyroid hormone action in the heart. Endocr 
Rev 2005;      26 (5): 704-728. 
49. Kahaly GJ, Nieswandt J, Mohr-Kahaly S. Cardiac risks of 
hyperthyroidism in the  elderly. Thyroid 1998; 8:1165–1169. 
50. Agner T, Almdal T, Thorsteinsson B, Agner E. A reevaluation of atrial 
fibrillation  in thyrotoxicosis. Dan Med Bull 1984; 31:157–159. 
51. Mohacsi A, Worum F, Lorincz I, Nagy E, Leövey A. Incidence of rhythm 
disorders in hyperthyrosis with special respect of old age form. Acta Med 
Hung 1990;  47:21–29. 
52. Iwasaki T, Naka M, Hiramatsu K, Yamada T, Niwa A, Aizawa T, 
Murakami M,  Ishihara M, Miyahara Y. Echocardiographic studies on the 
relationship between atrial fibrillation and atrial enlargement in patients 
with hyperthyroidism of Graves’ disease. Cardiology 1989; 76:10–17. 
53. Nakazawa K, Sakurai K, Hamada N, Momotani N, Ito K. Management of 
atrial  fibrillation in the post-thyrotoxic state. Am J Med 1982; 72:903-
906. 
54. Shimizu T, Koide S, Noh JY, Sugino K, Ito K, Nakazawa H. 
Hyperthyroidism and the management of atrial fibrillation. Thyroid 2002; 
12:489–493. 
55. Jayaprasad N, Francis J. Atrial fibrillation and hyperthyroidism. Indian 
Pacing and Electrophysiology Journal 2005; 5(4): 305-311. 
56. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. 
Mortality after the treatment of hyperthyroidism with radioactive iodine. 
N Engl J Med 1998; 338: 712–718. 
57. Bar-Sela S, Ehrenfeld M, Eliakim M. Arterial embolism in thyrotoxicosis 
with       atrial fibrillation. Arch Intern Med 1981; 141:1191–1192 . 
58. Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. 
Stroke     1988; 19:15–18. 
59. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of 
thromboembolism in atrial fibrillation. II. Echocardiographic features of 
patients at risk. Ann Intern Med       1992; 116:6–12. 
60. Hoffman I, Lowrey RD. The electrocardiogram in thyrotoxicosis. Am J 
Cardiol  1960; 8:893. 
61. Biondi B, Palmieri EA, Lombardi G, et al. Effects of thyroid hormone on 
cardiac function: the relative importance of heart rate, loading conditions, 
and myocardial contractility in the regulation of cardiac performance in 
human hyperthyroidism. J  Clin Endocrinol Metab 2002; 87: 968 –974. 
62. Mintz G, Pizzarello R, Klein I. Enhanced left ventricular diastolic 
function in       hyperthyroidism: noninvasive assessment and response to 
treatment. J Clin       Endocrinol Metab 1991; 73:146-150.  
63. Feldman T, Borow KM, Sarne DH, et al. Myocardial mechanics in 
hyperthyroidism: importance of left ventricular loading conditions, heart 
rate and contractile state. J Am Coll Cardiol 1986; 7: 967 –974. 
64. Lewis BS, Ehrenfelk EN, Lewis N, Gotsman MS. Echocardiographic left 
ventricular function in thyrotoxicosis. Am Heart J 1979; 97:460. 
65. Geffner DL, Herashman JM.  -Adrenergic blockade in the treatment of      
hyperthyroidism. Am J Med 1992; 93:61. 
66. Chopra IJ, Huang TS, Hurd RE, Solomon DH.A study of cardiac effects 
of   thyroid  hormones: Evidence for amelioration of the effects of 
thyroxine by sodium  iopate. Endocrinology 1984; 114:2039. 
67. Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. 
Stroke      1988; 19:15-18.  
68. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. 
Mortality   after  the treatment of hyperthyroidism with radioactive 
iodine. N Engl J Med 1998; 338:712–718. 
69. Osman F, Gammage MD, Franklyn JA. Hyperthyroidism and 
cardiovascular        morbidity and mortality. Thyroid 2002; 12:483–488. 
70. Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper DS, 
Ridgway EC. Radioactive iodine therapy and breast cancer. A follow-up 
study of hyperthyroid  women. Am J Epidemiol 1988; 127:969–980. 
71. Delit C,Silver S, Yohalen SB, Segal RL.Thyrocardiac disease and its 
management  with radio- active 
131
I.JAMA 1961; 176:262. 
72. Goland S, Shimoni S, Kracoff O. Dilated cardiomyopathy in 
thyrotoxicosis. Heart 1999; 81:444-449. 
73. De Carvalho Filho ET, Dias VL, Fernandes MC, Barbato A, Netto MP. 
Cardiac manifestations of hyperthyroidism in the elderly. Arq Bras 
Cardiol. 1991 Jan; 56(1): 31-37. 
74. Barbisan JN, Fuchs FD, Schaan BD. Prevalence of thyroid dysfunction 
  
in patients with acute atrial fibrillation attended at a cardiology 
 
 emergency room. Sao Paulo Med J 2003;121:159-62. 
 
75. Zargar AH, Bashir MI, Wine AI, Laway BA, Masoodi SR, Ganie MA et 
  
al. Clinical and endocrine aspects of thyrotoxicosis and its cardiovascular 
 
           complications. Annals of Saudi Medicine 2000;20:485-7. 
 
76. Mahesh PA, Vidyasagar B, Jayaraj BS. Principles and Interpretation of 
ChestX-rays. Orient Longman. 
 
 
Your digital receipt
This receipt acknowledges that Turnitin received your paper. Below you will find the receipt information
regarding your submission.
Paper ID 290455705
Paper title STUDY OF CARDIOVASCULAR MANIFESTATIONS INHYPERTHYROIDISM
Assignment
title Medical
Author Rajasekar 20101179 M.D. General Medicine
E-mail rajaneela7883@gmail.com
Submission
time 19-Dec-2012 06:52PM
Total words 8613
First 100 words of your submission
1 INTRODUCTION: Thyroid means (Greek thyreos means Shield, plus eidos, form) Thyroid
disorders is the commonest endocrinological disorder in clinical practice after diabetes mellitus.
Hyperthyroidism is defined in a state of excessive thyroid gland function. Thyrotoxicosis is defined as
the state of thyroid hormone excess and causes clinical Cardiac, Neurological, Ophthalmological ,
Dermatological, Gastro- intestinal , Endocrinological symptoms and signs. Hyperthyroidism caused
by Grave’s disease, Multi nodular goiter and Toxic adenomas constitute about majority of the cases
of thyrotoxicosis. Grave’s disease accounts for about 60-80% cases of thyrotoxicosis 1 . Thyroid
hormone exerts wide...
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